EXACT Therapeutics’ Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium

08 Jan 2026 08:30 CET

Oslo, Norway, 8 January 2026. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical-stage precision medicine company, is pleased to announce that a poster
on the ongoing Phase 2 ENACT trial in locally advanced pancreatic cancer
patients (NCT06850623) will be presented at the upcoming 2026 ASCO
Gastrointestinal (GI) Cancers Symposium, which takes place during 8-10 January
2026, in San Francisco, California.

The poster will be presented on 9 January.

Title: A phase 2 study to investigate the efficacy and safety of acoustic
cluster therapy with modified FOLFIRINOX in patients with locally advanced
pancreatic cancer

Poster #: TPS795

In collaboration with HonorHealth Research Institute, Scottsdale, AZ, United
States


About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases.
EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here: www.exact-tx.com  



For further information, please contact:

Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site